" class="no-js "lang="en-US"> FDA Archives - Medtech Alert
Monday, April 22, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors

Alentis Therapeutics, the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ […]

Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid Tumors

Lantern Pharma, an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary […]

FDA Advisory Committee Votes Unanimously to Confirm Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Early Alzheimer's Disease

BioArctic AB‘s partner Eisai announced that the US Food and Drug Administration’s (FDA) Peripheral and […]

FDA Accepts Biologics License Applications for exagamglogene autotemcel (exa-cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals and CRISPR Therapeutics today announced that the United States Food and Drug Administration (FDA) […]

Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM)

Rocket Pharmaceuticals, a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic […]

Injectafer® Approved in the U.S. for the Treatment of Iron Deficiency in Patients with Heart Failure

CSL Vifor today announced that the U.S. Food and Drug Administration (FDA) has granted its […]

GSK Receives US FDA File Acceptance for Jemperli (dostarlimab) plus Chemotherapy for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK has announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License […]

Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis

Kyverna Therapeutics, a cell therapy company with the mission of engineering a new class of […]

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency

Arcturus Therapeutics, a global late-stage clinical messenger RNA medicines company focused on the development of […]

AI Proteins Announces the Formation of a Scientific Advisory Board Made up of Experts in Biotech and FDA Drug Approval

AI Proteins, a growing biotechnology company that utilizes computational de novo protein design to create […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more